Home » Stocks » TRPX

Therapix Biosciences Ltd. (TRPX)

Jul 2, 2020 - Stock symbol was changed to TRPXY (reason: delisted from NASDAQ)
Stock Price: $0.320 USD 0.000 (0.00%)
Updated Jul 1, 2020 4:00 PM EDT
Market Cap 10.50M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 5.72M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jul 1, 2020
Last Price $0.320
Previous Close $0.320
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.301 - 0.400
Day's Volume 0
52-Week Range 0.250 - 4.690

News

Hide News
PRNewsWire - 6 months ago

TEL AVIV, Israel, July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the develo...

PRNewsWire - 6 months ago

TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the devel...

Investopedia - 11 months ago

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CARA, CRBP, CRON, GNLN, GWPH, MBII, NBEV, NTEC, OGI, PMD, SNDL, TLRY, VFF, ZYNE
Market Watch - 1 year ago

Shares of Therapix Biosciences fell 5% in morning trading after the Israeli drugmaker said it would continue to test its experimental cannabinoid-based therapy as an autism treatment.

Benzinga - 1 year ago

Cannabis-focused investment company SOL Global Investments Corp. (CSE: SOL) said Tuesday that its portfolio company, Heavenly Rx, Ltd., has entered into a memorandum of understanding with Ther...

Forbes - 1 year ago

There is a lot of hype regarding CBD and a lack of regulatory clarity. I discuss the big issues and identify some of the better players in the space among public-traded companies.

Other stocks mentioned: ACB, APHA, CGC, CRON, GWPH, TLRY, ZYNE

About TRPX

Therapix Biosciences, a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Bioscien... [Read more...]

Industry
Biotechnology
IPO Date
Mar 22, 2017
CEO
Gilad Bar-Lev
Country
Israel
Stock Exchange
NASDAQ
Ticker Symbol
TRPX
Full Company Profile

Financial Performance

Financial Statements